CRISPR-Cas proteins from bacteria are powerful tools for gene editing and molecular diagnostics. Expanding capacity of CRISPR to low cost, multiplexed assays of biomarkers is a key to future disease diagnostics, since multiple biomarker detection is essential for reliable diagnostics. Herein we describe a multiplexed assay in a 3D-printed 96-well plate with CRISPR-Cas13a immobilized in each well to target three circulating blood biomarker microRNAs (miRNAs 34c-5p, 200c-3p, and 30e-5p) for Alzheimer’s disease (ALZ). Immobilized Cas13a is equipped with different crRNAs complementary to each miRNA target. MiRNA binding to crRNA complements activates the collateral RNase activity of Cas13a, cleaving a quenched fluorescent reporter (RNaseAlert) with fluorophore and quencher connected by an RNA oligonucleotide to enable fluorescence measurements. We achieved ultralow limits of detection (LOD) of 0.74 fg/mL for miRNA 34c-5p, 0.70 fg/mL for miRNA 30e-5p, and 7.4 fg/mL for miRNA 200c-3p, with dynamic ranges from LODs up to about 1800 pg/mL. The accuracy of the assay was validated by spike-recovery studies and good correlation of levels of patient plasma samples vs. a referee method. This new approach provides selective, sensitive multiplex miRNA biosensing, and simultaneously accommodates analysis of standards and controls.
12 August 2024 in ACS Applied Materials & Interfaces
Enhancing the endosomal escape of nucleic acids remains a critical bottleneck to improve their therapeutic efficacy. Inspired by advancements in lipid nanoparticles, we describe a new chemical approach to deliver multi-tailed DNA surfactant conjugates with the potential for improved endosomal escape efficiency through enhanced membrane destabilizing properties. Previously we reported the successful delivery of therapeutic oligonucleotides to cells using single tailed DNA surfactant conjugates (DSCs) formed from enzyme degradable crosslinked micelles that we refer to as Nucleic Acid Nanocapsules (NANs). This work features the rational design of a new asymmetric set of hydrophobic crosslinkers using a synthetic approach which incorporates one or two alkyl chains and an esterase-labile group into a nonionic surfactant flanked by clickable azides. Through the covalent incorporation of these new crosslinkers into micelles and upon their enzymatic degradation within the cell, multi-tailed DNA surfactant conjugates are released which we show have superior transfection capabilities over single tailed DNA surfactant conjugates. We show that the multi-tailed DNA surfactant conjugates improve mRNA delivery and protein expression in vitro, as well as exhibit enhanced membrane disruption capabilities as seen by their dispersion in cells and through molecular dynamics simulations. Our chemical approach enables the formation of multi-tailed surfactants in situ, post micelle assembly, adding to the membrane destabilizing capacity of the delivered oligonucleotides. These studies are an exciting step towards using an oligonucleotide nanomaterial delivery platform as a “pro-drug” where the active therapeutic and potential for its cytosolic delivery is the product of the formulation’s degradation.